Adrenal Tumours - ERN eUROGEN

EA 3.3 Adrenal Tumours

Adrenal tumours are growths that develop in the adrenal glands, which are located on top of each kidney and are responsible for producing hormones that regulate blood pressure, metabolism, and the body’s response to stress. Adrenal tumours can be benign (non-cancerous) or malignant (cancerous). Benign tumours are more common and usually do not cause symptoms unless they are large or produce excess hormones. Malignant tumours can spread to other parts of the body and can cause symptoms such as abdominal pain, weight loss, and high blood pressure. Diagnosis of adrenal tumours usually involves blood tests to measure hormone levels, imaging tests, and sometimes a biopsy to examine a sample of the tumour tissue. Treatment for adrenal tumours depends on the type and size of the tumour, as well as the patient’s overall health. Treatment options may include surgery to remove the tumour, radiation therapy, chemotherapy, or medications to control hormone levels.

Expertise Area Coordinator and Vice-EAC

Expertise Area Coordinator: Hans Langenhuijsen

Vice-EAC: Nikola Knežević

Professor Nikola Knežević, MD, PhD, is the head of the Endourology ward at the Department of Urology, Clinical Hospital Center, Zagreb, Croatia, and the Professor of Urology at the University of Zagreb School of Medicine. He is ERN eUROGEN vice-EAC for Expertise Area 3.3 Adrenal Tumours.

His main scientific and clinical interests are minimally invasive procedures (laparoscopy, robotic), adrenal tumours, kidney cancer and testicular cancer. He is a member of the European Association of Urology, Croatian Medical Association, Croatian Urologic Society and Croatian Adrenocortical Carcinoma Study Group.

Conditions and Codes

Benign neoplasm of pituitary gland: ICD-10 Code D35.2
Cushing syndrome: ICD-10 Codes E24.0, E24.8
Adrenogenital disorders: ICD-10 Code E25.0
Phakomatoses, not elsewhere classified: ICD-10 Code Q85.8
Von Hippel-Lindau disease: ORPHAcode 892
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form: ORPHAcode 315311
Rare primary hyperaldosteronism: ORPHAcode 181415 / ICD-10 Code E26.0

Healthcare Providers

BE Leuven UZ, ES Barcelona Fundació Puigvert, ES Santander Valdecilla, HR Zagreb KBC, LT Vilnius SK, NL Nijmegen Radboudumc, SE Lund SUS

Additional Resources

Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Disease InfoSearch page and Genetic and Rare Diseases Information Center page.
Cushing’s Syndrome. Disease InfoSearch page and Genetic and Rare Diseases Information Center page.
Hyperaldosteronism. Disease InfoSearch page and Genetic and Rare Diseases Information Center page.
Pituitary Network Association. To support, pursue, encourage, promote, and, where possible, fund research on pituitary disorders in a sustained and full-time effort to find a cure for these illnesses. The PNA will disseminate information helpful to the medical community, the public, and to pituitary patients and their families on matters regarding early detection, symptoms, treatments and resources available to patients with pituitary disease.
von Hippel-Lindau disease. Disease InfoSearch page and Genetic and Rare Diseases Information Center page.